Floatz logo

Eloxatin

FAP

Parabilis Medicines, Inc.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the FAP cohort.

Asset / SponsorPhaseRating
Tegsedi
Ionis Pharmaceuticals, Inc.
Phase 3B
Eicosapentanoic Acid
S.L.A. Pharma AG
Phase 2/3B
FLUOROURACILUM
Parabilis Medicines, Inc.
Phase 1/2CCC
Nivolumab
Parabilis Medicines, Inc.
Phase 1/2CCC
TIPIRACIL
Parabilis Medicines, Inc.
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →